Hsp90 regulates p50(cdc37) function during the biogenesis of the activeconformation of the heme-regulated eIF2 alpha kinase.
Recent studies indicate that p50(cdc37) facilitates Hsp90-mediated biogenesis of certain protein kinases. In this report, we examined whether p50(cdc37) is required for the biogenesis of the heme-regulated eIF2 alpha kinase (HRI) in reticulocyte lysate. p50(cdc37) interacted with nascent HRI co-translationally and this interaction persisted during the maturation and activation of HRI. p50(cdc37) stimulated HRI's activation in response to heme deficiency, but did not activate HRI per se. p50(cdc37) function was specific to immature and inactive forms of the kinase. Analysis of mutant Cdc37 gene products indicated that the N-terminal portion of p50(cdc37) interacted with immature HRI, but not with Hsp90, while the C-terminal portion of p50(cdc37) interacted with Hsp90. The Hsp90-specific inhibitor geldanamycin disrupted the ability of both Hsp90 and p50(cdc37) to bind HRI and promote its activation, but did not disrupt the native association of p50(cdc37) with Hsp90. A C-terminal truncated mutant of p50(cdc37) inhibited HRI's activation, prevented the interaction of Hsp90 with HRI, and bound to HRI irrespective of geldanamycin treatment. Additionally, native complexes of HRI with p50(cdc37) were detected in cultured K562 erythroleukemia cells. These results suggest that p50(cdc37) provides an activity essential to HRI biogenesis via a process regulated by nucleotide-mediated conformational switching of its partner Hsp90.
Shao
J
J
Department of Biochemistry and Molecular Biology, Oklahoma State University, Stillwater, Oklahoma 74078, USA.
Grammatikakis
N
N
Scroggins
B T
BT
Uma
S
S
Huang
W
W
Chen
J J
JJ
Hartson
S D
SD
Matts
R L
RL
D000818:Animals; D016227:Benzoquinones; D018797:Cell Cycle Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D018833:Chaperonins; D029721:Drosophila Proteins; D004789:Enzyme Activation / Q000187:drug effects; D018841:HSP90 Heat-Shock Proteins / Q000378:metabolism*; D006418:Heme / Q000172:deficiency / Q000494:pharmacology*; D006801:Humans; D047029:Lactams, Macrocyclic; D046911:Macromolecular Substances; D018832:Molecular Chaperones; D009154:Mutation; D011485:Protein Binding / Q000187:drug effects; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D017434:Protein Structure, Tertiary; D011809:Quinones / Q000494:pharmacology; D011817:Rabbits; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D012156:Reticulocytes / Q000201:enzymology / Q000378:metabolism; D014407:Tumor Cells, Cultured; D019892:eIF-2 Kinase / Q000096:biosynthesis / Q000737:chemistry* / Q000378:metabolism*
D016227:Benzoquinones; C498362:CDC37 protein, human; D018797:Cell Cycle Proteins; D029721:Drosophila Proteins; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; D046911:Macromolecular Substances; D018832:Molecular Chaperones; D011809:Quinones; D011993:Recombinant Fusion Proteins; D006418:Heme; D019892:eIF-2 Kinase; D018833:Chaperonins; C001277:geldanamycin